Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
NYBC Ventures is a venture capital fund established by New York Blood Center Enterprises (NYBCe) in 2021, with a total commitment of $50 million. The firm is headquartered in Boston, Massachusetts, and is the first venture fund solely dedicated to advancing innovation in blood and cell-based therapies and technologies. NYBCe has over 60 years of experience in providing blood products and transfusion services, which informs the fund's investment strategy.
The Lindsley F. Kimball Research Institute (LFKRI), affiliated with NYBC, is recognized for its foundational, epidemiologic, and clinical research in the field. This extensive background positions NYBC Ventures uniquely within the healthcare and biotech sectors, particularly in blood-related fields. The firm currently manages a portfolio of 15 companies, reflecting its commitment to driving innovation in hematology and transfusion medicine.
NYBC Ventures invests primarily in early to mid-stage innovations, specifically targeting pre-seed, seed, seed-plus, and Series A funding rounds. The firm focuses on sectors such as healthcare and biotech, with a particular emphasis on blood and cellular therapies. Investment areas include therapeutics, devices, and solutions that address challenges in hematology, transfusion medicine, cell therapy, and infectious diseases.
NYBC Ventures seeks to partner with companies that are innovating in these critical areas, providing not just capital but also access to world-renowned researchers, cell manufacturing capacity, and deep domain expertise. The firm looks for founders who demonstrate a strong understanding of their market and possess a clear vision for their innovations. This approach ensures that portfolio companies are well-supported in their growth and development.
NYBC Ventures has a diverse portfolio of 15 companies, focusing on innovations in blood and cellular therapies. Notable portfolio companies include:
These companies exemplify NYBC Ventures' commitment to supporting early-stage innovations that address significant challenges in hematology and transfusion medicine. The firm’s portfolio reflects a strategic focus on therapeutic and technological advancements that can improve patient outcomes.
Christopher D. Hillyer, MD - General Partner. He serves as the President & CEO of NYBCe and has extensive experience in the healthcare sector, particularly in blood and transfusion services.
Jay Mohr - General Partner. He brings a wealth of experience in venture capital and healthcare investments, focusing on innovative technologies.
Meg Wood, MPH - Managing Director. She has a background in public health and healthcare investments, contributing to the firm’s strategic direction.
Kuan Yu - Senior Analyst. Kuan specializes in market analysis and due diligence for potential investments.
John Rosenthal - Chair. He has a strong background in healthcare management and governance.
Jung Choi - Manager. Jung focuses on operational support for portfolio companies.
Cristina Csimma - Manager. She brings expertise in regulatory affairs and compliance in the biotech sector.
David Kabakoff - Manager. David has experience in investment strategy and portfolio management.
To pitch to NYBC Ventures, founders should visit their website at nybcventures.com. It is advisable to include a comprehensive deck that outlines the business model, market analysis, and team qualifications. NYBC Ventures prefers warm introductions but will consider direct submissions through their website. Response times may vary, but founders can expect to hear back within a few weeks.
In 2021, NYBC Ventures launched with a commitment of $50 million, marking its entry into the venture capital space focused on blood and cellular therapies. The firm has since built a portfolio of 15 companies, including notable names like STAR Therapeutics and Veralox Therapeutics.
As of 2023, NYBC Ventures continues to expand its influence in the healthcare and biotech sectors, leveraging its affiliation with the New York Blood Center to drive innovation and support emerging companies in these critical fields.
What are the investment criteria for NYBC Ventures?
NYBC Ventures invests in early to mid-stage companies focused on blood and cellular therapies. They look for innovations that address challenges in hematology, transfusion medicine, and infectious diseases.
How can founders apply or pitch to NYBC Ventures?
Founders can pitch their ideas through the NYBC Ventures website at nybcventures.com. It is recommended to include a detailed business plan and information about the team and technology.
What makes NYBC Ventures different from other venture capital firms?
NYBC Ventures leverages over 60 years of expertise from the New York Blood Center, providing portfolio companies with access to world-renowned researchers, cell manufacturing capabilities, and deep domain knowledge in blood and cell therapies.
What is the geographic scope of NYBC Ventures?
NYBC Ventures primarily invests in North America, focusing on companies that are innovating in healthcare and biotech sectors.
What is the typical check size for investments?
NYBC Ventures invests in pre-seed, seed, seed-plus, and Series A rounds, with check sizes varying based on the stage and needs of the company.
What kind of post-investment involvement can portfolio companies expect?
NYBC Ventures provides operational support, access to research resources, and strategic guidance to help portfolio companies scale effectively.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.